Finding the right tests…
Emergency services available 24 x 7
Emergency services available 24 x 7
Finding the right tests…
ELISA
ANCA-MPO looks for antibodies against myeloperoxidase, an enzyme inside a type of white blood cell called a neutrophil. This particular antibody is the one most often linked to microscopic polyangiitis, a form of small-vessel vasculitis that tends to hit the kidneys hardest. Doctors order it when unexplained blood or protein shows up in urine alongside signs of inflammation elsewhere, such as skin rash, nerve pain, or lung symptoms, and vasculitis is suspected. Compared with the other major ANCA antibody, PR3, MPO-positive disease is more often confined to the kidney and tends to cause more severe scarring there, which affects how aggressively a doctor treats it and how the kidneys are followed up afterward.
The test detects and, if positive, often quantifies antibodies against myeloperoxidase using an immunoassay, sometimes alongside a separate immunofluorescence pattern called p-ANCA. A positive MPO-ANCA supports a diagnosis of ANCA-associated vasculitis, most often microscopic polyangiitis, though it can also appear in some cases of granulomatosis with polyangiitis and in certain drug-induced vasculitis. The result is read together with kidney function tests and urine findings, since MPO-ANCA disease is closely tied to kidney involvement and scarring rather than the airway and sinus disease more typical of the PR3 antibody.
MPO-ANCA and PR3-ANCA are grouped under the same test category, but they point toward different patterns of vasculitis. MPO-ANCA is linked more often with microscopic polyangiitis and with disease that stays limited to the kidney, causing more severe scarring on biopsy and a generally worse long-term kidney outcome than PR3-associated disease.
Doctors use the specific antibody, not just a general ANCA-positive result, to judge how closely to monitor the kidneys and how likely relapse is. Research following patients over time has found that people who are MPO-ANCA positive relapse less often than PR3-ANCA positive patients - roughly 20 to 30 percent within five years for MPO, compared with about 50 percent for PR3.
Studies looking at genetic risk have linked MPO-ANCA more closely with a particular set of HLA genes, HLA-DQ, while PR3-ANCA links more closely with HLA-DP. This genetic split is one reason researchers now treat MPO-ANCA and PR3-ANCA vasculitis as related but distinct conditions rather than one disease with two antibody types.
ANCA-MPO targets a different enzyme than ANCA-PR3, and the two are linked to different patterns of vasculitis - MPO more often with kidney-limited disease, PR3 more often with sinus and lung involvement. Your doctor may order both, since a person is usually positive for only one.
No. The antibody can appear in some infections and in certain drug reactions without true vasculitis being present. Your doctor combines the result with your symptoms, kidney function, and sometimes a biopsy before confirming a diagnosis.
MPO-ANCA levels can be followed over time to help judge disease activity and the chance of relapse, though the antibody level does not always track perfectly with how active the disease is. Repeat testing is more about the overall pattern than any single result.
This page is general information about the test, not medical advice. Your own report's reference ranges apply — please discuss your results with your doctor.
A negative result is reported as below the assay's cutoff, which is set by each lab's immunoassay. Ranges vary by lab, so check the reference value on your own report rather than a general number.
p-ANCA refers to the staining pattern seen under immunofluorescence, and MPO-ANCA is the specific antibody usually behind that pattern, though not always. Many labs now test for the MPO antibody directly rather than relying on the pattern alone.
There's no fixed preparation tied to this specific test. Ask your doctor or the centre when you book, especially if other blood tests are being drawn at the same visit.
Not necessarily. It means your kidneys need closer monitoring and, often, treatment aimed at controlling the underlying vasculitis before kidney function declines further. Your doctor decides the treatment plan based on your kidney tests and biopsy findings, not the antibody result alone.